Colitis nod puts J&J's Simponi one step closer to blockbuster

Johnson & Johnson's new-generation rheumatoid arthritis drug now has a new approval in ulcerative colitis. Simponi, which J&J ($JNJ) developed as a follow-up to its top-selling autoimmune therapy Remicade, could leap to blockbuster status with the help of this new indication, analysts say.

Remicade is itself approved for ulcerative colitis, and it brought in $6.1 billion last year, making it J&J's best seller. Simponi's $607 million in sales are obviously just a fraction of that, but analysts now figure it could hit $1.2 billion by 2016, Bloomberg reports. It's a subcutaneous treatment, while Remicade is an IV drug.

That's partly because the market for ulcerative colitis treatments is expected to double to $3.7 billion in the U.S., Japan and top European markets. But Simponi will have to compete not only with its sister treatment Remicade but also with Humira, AbbVie's ($ABBV) flagship product, which won approval in ulcerative colitis last fall. Analysts estimate that Humira could add $500 million to its sales through the new colitis use.

And then there's Pfizer's ($PFE) brand-new Xeljanz, approved for rheumatoid arthritis treatment. The company is developing Xeljanz in ulcerative colitis, too. And it's an oral treatment--no needles required.

- read the release from J&J
- see the Bloomberg story

Special Reports: Remicade - The 15 best-selling drugs of 2012 | Humira - The 15 best-selling drugs of 2012

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.